Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Mundipharma and Vectura announce plans to reformulate flutiform®
Details : The collaboration aims to reformulate flutiform (fluticasone propionate/formoterol fumarate) used in a pressurised metered-dose inhaler. It is being indicated for asthma.
Product Name : Flutiform
Product Type : Steroid
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint
Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.
Product Name : Flutiform
Product Type : Steroid
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
December 22, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidi...
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or i...
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PIM designation, early indication that CD101, next-generation echinocandin may be eligible for Early Access to Medicines Scheme in UK permits use of medicines not yet approved by regulatory authorities for treatment of invasive candidiasis and candidemia...
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
March 03, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rezafungin is a novel, once-weekly echinocandin, currently in Phase 3 clinical trials for both the treatment of invasive candidiasis and prophylaxis against severe invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation...
Product Name : CD101
Product Type : Peptide
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus
Details : Testing has demonstrated BETADINE's® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, Skin Cleanser, Gargle and Mouthwash and Throat Spray.
Product Name : Betadine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable